Johnson & Johnson announced a 5.3% increase in Q4 sales to $22.5 billion, slightly above expectations. Despite a dip in quarterly EPS, the company saw a 4.3% rise in annual sales a...
Johnson & Johnson has agreed to acquire Intra-Cellular Therapies Inc. for $14.6 billion, aiming to enhance its neuroscience portfolio and advance treatment for neuropsychiatric and...
Johnson & Johnson has announced a cash dividend of $1.24 per share for Q1 2025, payable on March 4 to shareholders recorded by February 18. The announcement led to a 0.40% rise in ...
